用于复发/难治性小儿急性淋巴细胞白血病的人源化靶向CD19嵌合抗原受体T（CAR-T）细胞 - Suppr

Humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells for relapsed/refractory pediatric acute lymphoblastic leukemia.

作者信息

Wang Shiyuan, Wang Xue, Ye Chunying, Cheng Hai, Shi Ming, Chen Wei, Qi Kunming, Wang Gang, Wu Qingyun, Zeng Lingyu, Li Zhenyu, Jing Guangjun, Zheng Junnian, Xu Kailin, Cao Jiang

机构信息

Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.

Cancer Institute, Xuzhou Medical University, Xuzhou, China.

出版信息

Am J Hematol. 2021 May 1;96(5):E162-E165. doi: 10.1002/ajh.26123. Epub 2021 Feb 21.

DOI:10.1002/ajh.26123

PMID:33580974

Abstract

摘要

相似文献

Humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells for relapsed/refractory pediatric acute lymphoblastic leukemia.用于复发/难治性小儿急性淋巴细胞白血病的人源化靶向CD19嵌合抗原受体T（CAR-T）细胞

Am J Hematol. 2021 May 1;96(5):E162-E165. doi: 10.1002/ajh.26123. Epub 2021 Feb 21.

Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.新型抗 CD19 嵌合抗原受体构建的 CD19 CAR T 在复发或难治性急性淋巴细胞白血病中的疗效和安全性。

J Hematol Oncol. 2020 Sep 7;13(1):122. doi: 10.1186/s13045-020-00953-8.

Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.异基因移植后复发的 B 细胞急性淋巴细胞白血病的 CD19 和 CD22 CAR-T 细胞治疗的联合应用。

Am J Hematol. 2021 Jun 1;96(6):671-679. doi: 10.1002/ajh.26160. Epub 2021 Mar 29.

Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia.局部产生的 CD19 CAR T 细胞导致髓性和髓外复发急性淋巴细胞白血病的临床缓解。

Am J Hematol. 2018 Dec;93(12):1485-1492. doi: 10.1002/ajh.25274. Epub 2018 Sep 26.

Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.半相合CD19嵌合抗原受体T细胞与干细胞共同输注在难治性急性淋巴细胞白血病中实现了完全供者植入。

J Hematol Oncol. 2016 Nov 25;9(1):131. doi: 10.1186/s13045-016-0357-z.

Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia.在复发/难治性急性淋巴细胞白血病患者中，人源化 CD19 靶向嵌合抗原受体 T（CAR-T）细胞具有强大的抗白血病活性。

Am J Hematol. 2018 Jul;93(7):851-858. doi: 10.1002/ajh.25108. Epub 2018 Apr 28.

Sustained Therapeutic Efficacy of Humanized Anti-CD19 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Acute Lymphoblastic Leukemia.人源化抗 CD19 嵌合抗原受体 T 细胞治疗复发/难治性急性淋巴细胞白血病的持久疗效。

Clin Cancer Res. 2020 Apr 1;26(7):1606-1615. doi: 10.1158/1078-0432.CCR-19-1339. Epub 2019 Nov 15.

Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.抗 CD19 嵌合抗原受体修饰 T 细胞疗法桥接异基因造血干细胞移植治疗复发/难治性 B 细胞急性淋巴细胞白血病：一项开放标签实用临床试验。

Am J Hematol. 2019 Oct;94(10):1113-1122. doi: 10.1002/ajh.25582. Epub 2019 Aug 2.

Donor-derived CAR-T Cells Serve as a Reduced-intensity Conditioning Regimen for Haploidentical Stem Cell Transplantation in Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: Case Report and Review of the Literature.供体来源的 CAR-T 细胞作为减轻强度预处理方案，用于治疗复发/难治性急性淋巴细胞白血病的单倍体相合干细胞移植：病例报告及文献复习。

J Immunother. 2018 Jul/Aug;41(6):306-311. doi: 10.1097/CJI.0000000000000233.

Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.嵌合抗原受体 T 细胞疗法治疗小儿 B-ALL：缩小早期和长期结局之间的差距。

Front Immunol. 2020 Aug 11;11:1985. doi: 10.3389/fimmu.2020.01985. eCollection 2020.

引用本文的文献

Allogeneic stem-cell transplantation following chimeric antigen receptor T-cell therapy for treatment of relapsed/refractory hematologic malignancy in children and young adults: a systematic review and meta-analysis.嵌合抗原受体T细胞疗法治疗儿童和青年复发/难治性血液系统恶性肿瘤后的异基因干细胞移植：一项系统评价和荟萃分析。

Clin Exp Pediatr. 2025 Sep;68(9):712-721. doi: 10.3345/cep.2025.00031. Epub 2025 Jul 4.

Chinese expert consensus on the application of intravenous immunoglobulin in hematological diseases.《静脉注射免疫球蛋白在血液系统疾病中应用的中国专家共识》

Front Med (Lausanne). 2025 Apr 1;12:1544025. doi: 10.3389/fmed.2025.1544025. eCollection 2025.

The costimulatory domain influences CD19 CAR-T cell resistance development in B-cell malignancies.共刺激结构域影响B细胞恶性肿瘤中CD19嵌合抗原受体T细胞耐药性的发展。

bioRxiv. 2025 Mar 4:2025.02.28.640707. doi: 10.1101/2025.02.28.640707.

The influence of CRS and ICANS on the efficacy of anti-CD19 CAR-T treatment for B-cell acute lymphoblastic leukemia.CRS 和 ICANS 对抗 CD19 CAR-T 治疗 B 细胞急性淋巴细胞白血病疗效的影响。

Front Immunol. 2024 Sep 27;15:1448709. doi: 10.3389/fimmu.2024.1448709. eCollection 2024.

CD19 CAR T cells for B cell malignancies: a systematic review and meta-analysis focused on clinical impacts of CAR structural domains, manufacturing conditions, cellular product, doses, patient's age, and tumor types.嵌合抗原受体 T 细胞治疗 B 细胞恶性肿瘤：一项系统性评价和荟萃分析，重点关注 CAR 结构域、制造条件、细胞产品、剂量、患者年龄和肿瘤类型对临床影响。

BMC Cancer. 2024 Aug 22;24(1):1037. doi: 10.1186/s12885-024-12651-6.

Advances in research on factors affecting chimeric antigen receptor T-cell efficacy.嵌合抗原受体 T 细胞疗效影响因素的研究进展。

Cancer Med. 2024 Jun;13(11):e7375. doi: 10.1002/cam4.7375.

Deciphering the importance of culture pH on CD22 CAR T-cells characteristics.解读培养pH值对CD22嵌合抗原受体T细胞特性的重要性。

J Transl Med. 2024 Apr 24;22(1):384. doi: 10.1186/s12967-024-05197-5.

Long-term outcomes following CAR T cell therapy: what we know so far.嵌合抗原受体 T 细胞疗法治疗后的长期结果：目前我们所了解的情况。

Nat Rev Clin Oncol. 2023 Jun;20(6):359-371. doi: 10.1038/s41571-023-00754-1. Epub 2023 Apr 13.

Novel Treatments for Pediatric Relapsed or Refractory Acute B-Cell Lineage Lymphoblastic Leukemia: Precision Medicine Era.小儿复发性或难治性急性B细胞系淋巴细胞白血病的新型治疗方法：精准医学时代

Front Pediatr. 2022 Jun 23;10:923419. doi: 10.3389/fped.2022.923419. eCollection 2022.

[Consensus of Chinese experts on chimeric antigen receptor T cell therapy for adult acute B-cell lymphoblastic leukemia (2022)].中国成人急性B淋巴细胞白血病嵌合抗原受体T细胞治疗专家共识（2022年）

Zhonghua Xue Ye Xue Za Zhi. 2022 Feb 14;43(2):89-95. doi: 10.3760/cma.j.issn.0253-2727.2022.02.001.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells for relapsed/refractory pediatric acute lymphoblastic leukemia.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献